CNS precision neuroscience biopharma preparing for commercial launch
Praxis Precision Medicines develops genetically informed CNS therapies and appears to be moving from clinical-stage to commercial-stage operations. Director-heavy hiring across healthcare, sales and regulatory, along with NDA/MAA submission work and field readiness, points to launch preparation. In parallel, an AWS multi-account build with Pulumi, Control Tower and GuardDuty, plus Veeva PromoMats and QMS, shows GxP-grade infrastructure being put in place.
Notable leadership hires: Combination Product Program Lead, Sales Business Director, Regional Sales Director
Praxis Precision Medicines is a public biopharmaceutical company headquartered in Boston, MA, with 201–500 employees. It develops therapies for neurological disorders driven by an imbalance between neuronal excitation and inhibition, drawing on insights from genetic epilepsies. Its pipeline spans rare and more common brain disorders, including work in essential tremor. Discovery runs on two proprietary platforms: Cerebrum for small molecules and Solidus for antisense oligonucleotides. Hiring is concentrated in the United States.
Praxis uses AWS (Lambda, RDS, DynamoDB, Control Tower), Pulumi, TypeScript, Python, Snowflake, Databricks, dbt, Veeva Vault, PromoMats and QMS, SAP, Salesforce and Microsoft Dynamics 365.
Yes. Hiring is accelerating, and open leadership roles include a Sales Business Director and a Regional Sales Director, all based in the United States. This hiring lines up with commercial launch preparation.
Current work includes FDA regulatory strategy, NDA/MAA submissions, analytical method transfer and validation, product launch execution, ERP and CRM integrations, and an AWS multi-account architecture.
Other companies in the same industry, closest in size
Praxis Precision Medicines, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.